Cannabis Rescheduling Hearing Final Wrap: What the Record Says for $MSOS, $TLRY and $CGC

1. What actually happened on July 15

The most important correction is also the simplest: July 15 was the end of the scheduled evidentiary hearing, not the day of the final ruling. The official DEA schedule reserved the final day for cross-examination and redirect of the opposing states’ witnesses, followed by a closing statement from Chief Administrative Law Judge Derek C. Julius. The parties were not scheduled to deliver conventional live closing arguments.

At publication time on July 16, the DEA’s public marijuana-rescheduling page had not posted a recommended decision, a final rule or a complete official hearing transcript. That means any detailed description of courtroom exchanges must be separated into two categories: facts confirmed by the official docket and accounts reported by attorneys, journalists or observers who attended the non-broadcast proceeding.

The formal sequence now moves away from witness testimony and toward written legal argument. The designated parties will submit proposed findings and post-hearing briefs. Judge Julius will then review the testimony, exhibits and legal arguments and issue a recommended decision. That recommendation is important, but it is not the final agency action.

2. Why this hearing was structurally unusual

The government was the formal proponent of the broader Schedule III proposal and bore the burden of supporting it. Every non-government participant selected by the DEA opposed the change; Louisiana later withdrew from the opposing states group. That produced an “upside-down” proceeding: the DEA defended a rule that would reduce marijuana’s federal schedule, while anti-rescheduling organizations, law-enforcement representatives, physicians, drug-testing interests and opposing states attempted to weaken the government’s evidentiary foundation.

The exclusion of pro-rescheduling industry groups and advocates was controversial, but it did not automatically turn the hearing into an anti-cannabis verdict. The government still carried the burden of supporting the proposed rule, presented its own witnesses and had the opportunity to cross-examine opposition witnesses. At the same time, the one-sided participant list matters because it shaped which evidence entered the record and which arguments were repeatedly emphasized.

There are two competing interpretations of that structure:

• Constructive interpretation: allowing opponents to develop their strongest case could make a future Schedule III rule more durable by showing that the agency considered contrary evidence before acting.
• Risk interpretation: excluding supportive parties may leave gaps in the record and strengthen later arguments that important scientific, medical and industry evidence was not fully tested in the hearing.

Both interpretations can be true. The hearing gave opponents a serious opportunity to build an appellate record, but it also forced their claims into the open, where several proved less directly relevant to the legal criteria than the political rhetoric suggested.

3. The government’s core case survived

The government’s case was narrow by design. It did not need to prove that marijuana is harmless, appropriate for every patient or equivalent to an FDA-approved pharmaceutical. The central statutory task was to support the findings required for Schedule III: a potential for abuse lower than substances in Schedules I and II, a currently accepted medical use in treatment in the United States, and a dependence profile consistent with Schedule III.

Government witnesses relied on the HHS and FDA scientific review and on clinical evidence supporting at least one accepted medical use. The government’s medical-use theory focused on conditions including pain, nausea and vomiting, and anorexia associated with a medical condition. Its comparative-abuse argument did not claim that marijuana has no abuse potential; it argued that the relevant potential is lower than that of Schedule I and II comparators.

This distinction matters. Schedule III is not a declaration that a substance is safe in all circumstances. It is a comparative legal classification. Much of the opposition evidence described real risks—high-potency products, cannabis use disorder, psychosis, impaired driving, youth exposure and inconsistent dosing—but risk alone does not answer the precise scheduling question. The judge and the DEA Administrator must determine whether those risks defeat one or more of the statutory findings required for Schedule III.

Accepted medical use remains the legal hinge

The strongest government position is that one qualifying currently accepted medical use is enough to defeat Schedule I’s “no accepted medical use” requirement. The HHS and FDA findings carry substantial weight in the process, and the government placed both agency-process testimony and clinical-use testimony into the record.

The hearing therefore did not reduce to a referendum on whether modern dispensary products resemble conventional prescription drugs. The narrower question is whether the record supports at least one accepted medical use under the legal framework the government applied. That remains the most important issue for Judge Julius.

4. Where the opposition created genuine risk

The anti-rescheduling case was not uniformly strong. Some witnesses focused on consequences that Schedule III would not actually cause, while others attacked the scientific and legal foundation more directly. The latter testimony is what matters most now.

The CAMU-test challenge

One of the most consequential lines of attack concerned the shift from the DEA’s traditional five-part test for “currently accepted medical use” to the newer two-part framework used by HHS. Opposition witnesses argued that the older test demanded reproducible chemistry, well-controlled studies, accepted safety and broader expert acceptance, while the newer framework placed more weight on widespread medical use under state programs and credible scientific support.

A DEA pharmacologist called under subpoena reportedly testified that an internal agency analysis had identified gaps in the HHS approach and concluded that marijuana did not satisfy the older five-part test. The government did not cross-examine that witness, leaving the testimony formally unrebutted in the live record. The government can still answer the argument in post-hearing briefs, including by maintaining that the older test is no longer the operative standard.

This is probably the opposition’s most litigation-ready issue because it concerns not merely the weight of the science but the legal method used to define accepted medical use.

Botanical variability and the potency mismatch

Several opposition witnesses argued that the cannabis used in clinical studies is not the same as the high-potency, highly variable product sold in many state markets. Their case emphasized batch inconsistency, uncertain dosing, different delivery systems and the gap between controlled research material and commercial dispensary products.

That critique does not automatically defeat Schedule III, but it gives the opposition a coherent argument: evidence supporting the medical use of certain preparations may not justify a broad scheduling change covering the full range of modern marijuana products. The government’s response is that the Controlled Substances Act asks whether marijuana has an accepted medical use, not whether every state-market product is standardized like an approved drug.

This tension—accepted medical use versus product-level uniformity—will likely appear again in the written briefs and in any later court challenge.

Impaired driving, workplace testing and law enforcement

The opposition also built a public-safety record around drugged driving, workplace impairment, diversion and enforcement burdens. These are politically powerful themes, but the hearing exposed limits in several versions of the argument.

According to reporting from observers, the drug-testing representative acknowledged that private employers could continue testing under company policy even after rescheduling. Federally mandated testing programs for safety-sensitive transportation workers present a more specific regulatory issue, but Schedule III would not erase all workplace-testing authority.

Law-enforcement testimony also sometimes blurred rescheduling with deregulation or legalization. Cross-examination clarified that moving marijuana to Schedule III would not legalize recreational possession, authorize interstate commerce, eliminate federal controls or make diversion lawful. That correction weakens arguments based on consequences that the proposed rule does not itself produce.

5. The most important reported concession—and the necessary caveat

The most widely discussed pro-Schedule III moment came during the testimony of Harvard psychobiology professor Bertha Madras, a prominent opponent of rescheduling. Multiple industry reports and courtroom observers said that, under government cross-examination, she acknowledged that marijuana satisfies the statutory criteria associated with Schedule III. She also reportedly agreed that marijuana does not produce the respiratory-depression deaths associated with opioids because cannabinoid receptors do not regulate breathing in the same manner.

Those reported concessions are meaningful because they came from an opposition expert whose direct testimony attacked the medical-use evidence, product consistency and research base. They support the government’s comparative-safety argument and complicate a categorical Schedule I position.

This distinction is essential. The concession may become one of the strongest passages in the final record, but its exact wording, context and legal significance should be checked again when the DEA publishes the transcript.

6. Final hearing scorecard

7. Our final assessment so far

The fairest conclusion is not “Schedule III won” and not “the hearing failed.” The case for broader rescheduling emerged intact but bruised.

The government still has several structural advantages. The policy direction is explicit, the proposed rule is already on the table, HHS and FDA supplied the scientific foundation, and the April 2026 action already placed FDA-approved and qualifying state-licensed medical marijuana products into Schedule III. The hearing did not erase those facts.

Opponents nevertheless did enough to prevent an easy victory narrative. They developed a detailed challenge to the accepted-medical-use framework, highlighted the mismatch between research products and modern high-potency retail cannabis, placed public-safety evidence into the record and preserved multiple issues for judicial review. The government’s decision not to cross-examine several witnesses may place more pressure on its post-hearing briefs.

Our present rating is therefore:

The strongest bullish interpretation is that the hearing did what an agency needs before issuing a durable rule: it exposed and tested the opposition’s best arguments without destroying the government’s core findings. The strongest bearish interpretation is that the opposition introduced enough scientific and procedural doubt to support a negative recommendation, a narrower final action or a successful court challenge.

At this stage, the bullish interpretation appears somewhat stronger—but not by enough to treat the outcome as settled.

8. What happens next

1. Post-hearing briefs and proposed findings. The parties will organize the testimony and exhibits into formal legal arguments. This phase may be more important than the final day’s headlines because it tells the judge exactly how each side believes the record satisfies—or fails—the statutory criteria.
2. Recommended decision from Chief ALJ Derek Julius. The judge will issue findings and a recommendation. There is no publicly guaranteed date for that decision.
3. Exceptions. Parties have 20 days to file exceptions to the recommended decision under DEA procedure.
4. Certification of the record. The transcript, exhibits, findings, briefs and exceptions move to the DEA Administrator.
5. Final agency action. The DEA Administrator decides whether to adopt, reject or modify the proposed broader Schedule III rule. A completed rescheduling action would require publication in the Federal Register.
6. Judicial review. The final agency action can be challenged in federal court. Separate litigation is already testing the legality of the April 2026 medical-marijuana order.

The process may move faster than historic DEA scheduling cases because the December 2025 executive order called for expeditious completion and the 2026 hearing itself operated under a compressed schedule. “Faster” does not mean immediate. Administrative briefing, a reasoned recommendation, agency review and likely litigation still require time.

9. What Schedule III would change—and what it would not

The potential economic change: Section 280E

Internal Revenue Code Section 280E denies ordinary business deductions to businesses trafficking in substances listed in Schedule I or II. That is why Schedule III matters economically. A broad final rule covering the remaining marijuana market could remove the 280E burden for businesses dealing in products covered by the new classification, potentially improving after-tax cash flow and the credibility of U.S. cannabis business models.

The April 2026 order already created Schedule III treatment for FDA-approved marijuana products and qualifying state-licensed medical marijuana products. The current proceeding addresses the broader remainder of marijuana, including the adult-use side of the market.

What Schedule III does not automatically deliver

• It does not federally legalize recreational marijuana.
• It does not automatically authorize interstate commerce.
• It does not automatically enact comprehensive cannabis banking reform.
• It does not guarantee Nasdaq or NYSE listings for U.S. plant-touching operators.
• It does not eliminate state licensing, testing, packaging or product-safety rules.
• It does not remove the possibility of federal enforcement outside the permitted framework.

This is why the cannabis trade must separate tax reform, federal legality, banking, exchange access and interstate commerce. They are connected themes, but they are not the same catalyst.

10. Read-through for the major trading proxies

For trading purposes, $TLRY and $CGC may continue to react fastest because they are familiar, liquid Nasdaq names. For fundamental economic exposure, $MSOS remains the cleaner listed basket through which the market can express a view on U.S. operators and possible broader 280E relief.

11. The three scenarios from here

Constructive scenario

Judge Julius recommends broader Schedule III treatment, the DEA Administrator adopts the recommendation on an accelerated timetable and litigation does not immediately block implementation. U.S.-focused cannabis valuations begin to reflect improved tax economics, while liquid Nasdaq proxies experience a renewed policy-driven momentum phase.

Base scenario

The recommendation is positive but heavily qualified, post-hearing briefing and agency review take months, and court challenges remain active. Cannabis stocks continue to trade in bursts around filings, leaks, procedural orders and political statements rather than around one clean catalyst date.

Risk scenario

The judge finds the record insufficient for the proposed broad Schedule III rule, or the DEA Administrator declines to adopt a favorable recommendation. The April medical framework remains a separate and contested policy track, while the market unwinds expectations for immediate adult-use 280E relief.

The base scenario is currently the most realistic. The direction may be constructive, but the path is unlikely to become simple merely because testimony ended.

12. The next verifiable catalysts

• Publication of the official hearing transcript and exhibits.
• A briefing order or confirmed deadlines for proposed findings and post-hearing briefs.
• The government’s written response to the CAMU-test and product-variability attacks.
• Chief ALJ Julius’s recommended decision.
• Any exceptions filed within the 20-day window.
• A DEA final rule—or an order declining to finalize the proposal.
• Developments in the D.C. Circuit litigation challenging the April 2026 medical-marijuana action.
• Company disclosures explaining how individual operators interpret 280E eligibility and regulatory coverage.

Until those documents appear, courtroom summaries should be treated as useful but provisional. The official transcript and written briefs will be more reliable than social-media fragments or one-line “Schedule III won” claims.

Bottom line

The July 15 hearing closed without the binary answer many traders wanted. That is not a disappointment in the process; it is how the process was designed. The government now has to convert its scientific and medical case into a legally durable written argument. Opponents will try to convert uncertainty, product variability and public-safety concerns into a reason to reject or narrow the proposal.

So far, the broad Schedule III case has survived. It was not untouched, and it is not guaranteed. But the hearing did not produce evidence strong enough to declare the government’s proposal dead. Some opposition arguments were weakened by cross-examination, and the most important reported concession came from one of the opposition’s own leading experts.

Last verified: July 16, 2026, against the DEA docket, Federal Register materials and the sources listed above.